* Note: Prices are in Million (M) USD.
Description:
MaxCyte Inc. (MXCT) is a leading innovator in cell-engineering solutions, renowned for its proprietary Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins across diverse cell types. Catering to a broad spectrum of clients, including major biopharmaceutical companies and research institutions, MaxCyte plays a critical role in the rapidly evolving cell and gene therapy market. The company's advanced platforms are essential for the development of cutting-edge cell-based therapies and vaccines, positioning MaxCyte to capitalize on significant growth opportunities in the healthcare sector. With a steadfast dedication to advancing transformative treatment options, MaxCyte is well-equipped to address the escalating global demand for innovative therapeutic modalities.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $20 M
Debt : $1 M
EBITDA : $-41 M
Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health care
Industry: Medical devices
Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.
Using default values for calculation.
Forward PE Ratio (using default values): 20.00
Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 14 overlapping fiscal years (max 20).Average Free Cash Flow: $-13 M
Average Revenue: $22 M
Revenue Converted To Free Cash Flow (%): -60.8%
Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2025-12-31): $33 M
Revenue 5 Years Ago (2020-12-31): $26 M
Total Growth over 5 Years: 26.2%
5-Year Revenue CAGR (Historical): 4.8%
Forward 5-Year CAGR (Tapered): 4.3%
Since historical Revenue CAGR is between 0 - 5, 1 point assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2025-12-31): $106 M
Share Count 5 Years Ago (2021-12-31): $91 M
Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-0.26
Trailing 12-Month Earnings Per Share (EPS): $-0.29
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%
⚠️ Caution: Negative earnings detected — Further research is recommended - Next Fiscal Yr EPS: $-0.26
- Latest/TTM EPS: $-0.29
Since Dividend Per Share is less than or equal to 0, 0 point assigned.
Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 10 valid ROE years (max 20).Average ROE: -39.8%
Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $0.71
52-Week Low: $0.64
Threshold Price (15% Above 52-Week Low): $0.74
Since Current price is within 15% threshold, 5 points assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $80 M
Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 0.5% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
No positive free cash flow found (TTM or annual) to compute Owners' Earnings per share.
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low.
Consider other factors in your valuation.
Value-Trade has assigned 12 points to above MaxCyte Inc (MXCT) stock.
Fair Value PE 12, Industry Based PE 18, Growth Based PE 15, Risk-Free Anchored PE (25% MoS) 17.65. Based on these 4 values, average assigned is 15.66. The fair value of MaxCyte Inc (MXCT) stock cannot be calculated since EBITDA and EPS are either 0 or negative.
